Inotuzumab Ozogamicin: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), AOTMIT (Poland) and HAS (France), among others, recommended or restricted inotuzumab ozogamicin, while DMC (Denmark) did not recommend it.
Where inotuzumab ozogamicin met resistance it was usually narrowed rather than refused: 4 of 10 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
Assessment has run over 9.2 years, from 25 May 2017 at AWMSG (Wales) to 2026 at PBAC (Australia).
AIFA (Italy) changed its position: recommended on 7 Jun 2018, restricted by 7 Jun 2018.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
4 distinct indication wordings are recorded for inotuzumab ozogamicin by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 12 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess inotuzumab ozogamicin, on 25 May 2017; PBAC (Australia) did not open a file until 2026 — an unusually long tail of 9.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 7 of 12 dated records fall in 2018 alone.
Restriction is doing real work here: 4 of 10 decisive outcomes narrowed inotuzumab ozogamicin to a subgroup rather than accepting or refusing it outright, at AIFA (Italy), AOTMIT (Poland) and NICE (England) among others.
2 of the 10 agencies here assessed inotuzumab ozogamicin more than once, AIFA (Italy) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for inotuzumab ozogamicin.
The full ledger for inotuzumab ozogamicin reads 5 recommended, 4 restricted, 1 advice and 1 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 21 Sep 2022 | Re-assessment of SMR and ASMR | SMR substantial · ASMR V | source |
| AOTMIT (Poland) | 6 Aug 2019 | programu lekowego : ,,Leczenie inotuzumabem ozogamycyny dorosłych chorych z nawrotową lub oporną na leczenie ostrą biała… | recommended conditionally | source |
| HIRA (South Korea) | 26 Jul 2019 | 급성 림프모구성 백혈병 | reimbursement appropriate | source |
| NYE METODER (Norway) | 21 Oct 2018 | Behandling av tilbakevendende eller behandlingsrefraktær akutt lymfoblastisk leukemi | introduced | source |
| NICE (England) | 19 Sep 2018 | NICE TA541 | recommended (optimised) | source |
7 further decisions for inotuzumab ozogamicin, across 6 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
- blinatumomab — same ATC class L01F — Antineoplastics
Coverage: 12 decisions for inotuzumab ozogamicin from 10 agencies, 2017 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.